| Autor: |
Younus MM; Iraqi Pharmacovigilance Center, Ministry of Health, Baghdad, Iraq.; International Society of Pharmacovigilance Patient Engagement Special Interest Group, London, UK., Alkhakany M; International Society of Pharmacovigilance Patient Engagement Special Interest Group, London, UK.; Healthcare Affair, Boehringer Ingelheim, Dubai, United Arab Emirates., Bahri P; International Society of Pharmacovigilance (ISoP)-Special Interest Group on Medicinal Product Risk Communication, European Medicines Agency, Pharmacovigilance Office, Amsterdam, The Netherlands., Caro A; International Society of Pharmacovigilance (ISoP), Pharmacy Career Director of Pontificia Universidad Javeriana, Bogotá, Colombia., Rostom H; International Society of Pharmacovigilance (ISoP)-Egypt Chapter, Cairo, Egypt.; Faculty of Pharmacy, MSA University, 6th of October City, Giza, Egypt., Ndagije HB; National Drug Authority, Directorate of Product Safety, Kampala, Uganda., Elhawary MA; Egyptian Ministry of Health and Population, Central Administration for Pharmaceutical Affairs, Cairo, Egypt. mohamed.ahmed.elhawary19@gmail.com.; Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. mohamed.ahmed.elhawary19@gmail.com. |
Full text from SpringerLink